Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
38.77
-0.54 (-1.37%)
At close: Dec 5, 2025, 4:00 PM EST
38.51
-0.26 (-0.67%)
After-hours: Dec 5, 2025, 7:58 PM EST
Cogent Biosciences Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Cogent Biosciences stock have an average target of 28.08, with a low estimate of 9.00 and a high estimate of 50. The average target predicts a decrease of -27.57% from the current stock price of 38.77.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cogent Biosciences stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 6 | 6 | 6 | 6 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 3 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 11 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $21 → $50 | Strong Buy | Maintains | $21 → $50 | +28.97% | Nov 13, 2025 |
| Baird | Baird | Hold Maintains $14 → $34 | Hold | Maintains | $14 → $34 | -12.30% | Nov 11, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $18 → $50 | Buy | Maintains | $18 → $50 | +28.97% | Nov 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | -45.83% | Nov 4, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $30 → $44 | Buy | Maintains | $30 → $44 | +13.49% | Oct 21, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
47.18M
EPS This Year
-2.29
from -2.46
EPS Next Year
-1.78
from -2.29
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 166.6M | ||||
| Avg | n/a | 47.2M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.06 | -0.92 | ||||
| Avg | -2.29 | -1.78 | ||||
| Low | -2.42 | -2.19 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.